Tariq Kas­sum jumps from Ob­sid­i­an to Cel­sius helm; Quell Ther­a­peu­tics taps Iain McGill as new CEO

Tariq Kas­sum Linkedin

→ Cam­bridge, Mass­a­chu­setts-based Cel­sius Ther­a­peu­tics — which was launched in 2018 and backed by Third Rock Ven­tures and GV — has tapped Tariq Kas­sum to the helm. Kas­sum suc­ceed­ed Alex­is Borisy, who has been in­ter­im CEO and who stay as chair­man of the board of di­rec­tors.

Borisy re­cent­ly made an un­ex­pect­ed ex­it from Third Rock, be­fore their record $770 mil­lion fund for its next wave of in­vest­ments in the life sci­ence field.

Kas­sum was the COO at Ob­sid­i­an Ther­a­peu­tics, fol­low­ing stints at Mil­len­ni­um Phar­ma­ceu­ti­cals and Take­da.

Alex Sapir Re­Vi­ral

Alex Sapir has suc­ceed­ed Ed­dy Lit­tler as CEO of Re­Vi­ral — a stick­ler in the tough res­pi­ra­to­ry syn­cy­tial virus (RSV) field — and been elect­ed to the com­pa­ny’s board of di­rec­tors. Lit­tler will as­sume the po­si­tion of COO in­stead. Pri­or to join­ing Re­Vi­ral, Sapir was CEO and pres­i­dent at Do­va Phar­ma­ceu­ti­cals, help­ing raise $160 mil­lion in an IPO and fol­low-on of­fer­ings. In ad­di­tion, Sapir has had stints at Unit­ed Ther­a­peu­tics and GSK.

Iain McGill Linkedin

Weeks af­ter launch­ing out of Syn­cona’s crib, Quell Ther­a­peu­tics — which is spe­cial­iz­ing in the de­vel­op­ment of en­gi­neered Treg cell ther­a­pies — wel­comes Iain McGill as its CEO. Pri­or to join­ing Quell, McGill served as se­nior vice pres­i­dent in Eu­rope and the rest of the world for Jazz Phar­ma­ceu­ti­cals. Be­fore that, McGill had a stint at EU­SA Phar­ma and he al­so worked in var­i­ous po­si­tions in the field of trans­plan­ta­tion and im­munol­o­gy at Wyeth, No­var­tis and Roche Phar­ma­ceu­ti­cals.

James Ward-Lil­ley, CEO of res­pi­ra­to­ry drug de­vel­op­er Vec­tura Group, is step­ping down from both his po­si­tion and the board. Cur­rent CFO Paul Fry will step in as in­ter­im CEO, in ad­di­tion to his cur­rent re­spon­si­bil­i­ties. A search for a new suc­ces­sor will be­gin im­me­di­ate­ly.  

Jes­si­ca Mar­tins­son Sprint Bio­science

Sprint Bio­science CEO An­ders Åberg is step­ping down from his po­si­tion af­ter 10 years in the role, and cur­rent op­er­a­tional man­ag­er and co-founder Jes­si­ca Mar­tins­son will re­place him as the act­ing CEO. Åberg will re­tain his share­hold­ing and re­main as a se­nior ad­vi­sor to the com­pa­ny.

Louis Kay­i­talire Linkedin

→  Cam­bridge, Eng­land-based F-star has ap­point­ed Big Phar­ma vet Louis Kay­i­talire as its CMO. Kay­i­talire will over­see the de­vel­op­ment of F-star’s lead prod­uct can­di­date FS118 — a LAG-3/PD-L1-tar­get­ing tetrava­lent bis­pe­cif­ic an­ti­body cur­rent­ly in a Phase I clin­i­cal tri­al. He will al­so lead the clin­i­cal strat­e­gy and op­er­a­tions for F-star’s pipeline of bis­pecifics, in­clud­ing FS120 and FS222, which are on track for IND sub­mis­sions this year. Kay­i­talire has over 20 years of ex­pe­ri­ence in on­col­o­gy and im­muno-on­col­o­gy ac­cu­mu­lat­ed over the years at Bris­tol-My­ers Squibb, Cel­gene and Eli Lil­ly.

Thomas Schi­neck­er Roche

→ Swiss gi­ant Roche has un­veiled the new head of its $13 bil­lion di­ag­nos­tics unit — one day af­ter the FDA sanc­tioned the ac­cel­er­at­ed ap­proval of the com­pa­ny’s lat­est an­ti­body-drug con­ju­gate. Thomas Schi­neck­er — who has been with the com­pa­ny since 2003 — is be­ing pro­mot­ed to CEO of Roche Di­ag­nos­tics, and will be­gin his tenure from Au­gust 1, the com­pa­ny said. Schi­neck­er will re­place Roland Diggel­mann, who left his post last Au­gust.

In ad­di­tion, Roche board mem­ber Pe­ter Vos­er — who has been with the com­pa­ny since 2011 — has elect­ed to step down to fo­cus on his role as in­ter­im CEO of ABB. Fur­ther­more, Roche’s head of group com­mu­ni­ca­tions, Stephan Feld­haus, is al­so leav­ing and will be re­placed by Bar­bara Schaedler, who is cur­rent­ly head of pub­lic af­fairs at pri­vate en­er­gy com­pa­ny E.ON SE.

Unum Ther­a­peu­tics has en­list­ed sev­er­al C-suite mem­bers on its on­go­ing quest for a new kind of T cell ther­a­py. Matthew Os­borne, a for­mer VP of cor­po­rate af­fairs, com­mu­ni­ca­tions and in­vestors re­la­tions at Voy­ager Ther­a­peu­tics, is the new CFO. Take­da vet Jes­si­ca Sachs has been pro­mot­ed to CMO, re­plac­ing Michael Vas­con­celles. In ad­di­tion, Mert Ak­tar has been ap­point­ed to the new­ly cre­at­ed role of head of busi­ness and cor­po­rate de­vel­op­ment af­ter 8 years at Shire.

Michael Vas­con­celles has been re­cruit­ed by Flat­iron Health to serve as its CMO. Vas­con­celles just left the same po­si­tion at Unum Ther­a­peu­tics. Vas­con­celles’ pre­vi­ous stints in­clude serv­ing at Take­da/Mil­len­ni­um, Gen­zyme and Sanofi On­col­o­gy. Cur­rent­ly, he is as a clin­i­cal in­struc­tor in med­i­cine at Har­vard Med­ical School and is a prac­tic­ing on­col­o­gist and as­so­ciate physi­cian at the Dana-Far­ber Can­cer In­sti­tute and Brigham & Women’s Hos­pi­tal in Boston.

→ Af­ter a re­cent stint as vice pres­i­dent of glob­al reg­u­la­to­ry af­fairs and qual­i­ty as­sur­ance at Charleston Lab­o­ra­to­ries, Mark Man­nebach is join­ing Eiger Bio­Phar­ma­ceu­ti­cals as its vice pres­i­dent of glob­al reg­u­la­to­ry af­fairs.

Mark Man­nebach Linkedin

“Eiger’s pipeline is now late-stage with planned glob­al reg­u­la­to­ry ac­tiv­i­ties in­clud­ing an NDA and MAA for Prog­e­ria and Progeroid Laminopathies, en­roll­ment of a glob­al Phase III study for Lon­a­farnib in HDV, and End of Phase 2 meet­ings for Pegin­ter­fer­on Lamb­da in HDV and Avex­i­tide in Post-Bariatric Hy­po­glycemia,” said David Cory, pres­i­dent and CEO of Eiger. “Mark’s glob­al reg­u­la­to­ry ex­per­tise and ex­pe­ri­ence will strength­en our lead­er­ship team and ex­e­cu­tion.”

Some of Man­nebach’s pre­vi­ous stints in­clude roles at Sanofi, Pfiz­er, Co­vi­di­en and Mallinck­rodt Phar­ma­ceu­ti­cals.

Zy­la Life Sci­ences re­cruit­ed Jef­frey Wilkins as its CMO and se­nior vice pres­i­dent. Wilkins joins the com­pa­ny from the same po­si­tion at Lyc­era. Pri­or to his time at Lyc­era, Wilkins had stints at Nex­ep­tion Ther­a­peu­tics, Cep­taris Ther­a­peu­tics, Acte­lion and GSK.

Deepi­ka Jalota Linkedin

PMV Phar­ma­ceu­ti­cals — a biotech fo­cused on p53-tar­get­ed small mol­e­cule drugs for can­cer — an­nounced the ap­point­ment of Deepi­ka Jalota as its se­nior vice pres­i­dent and head of reg­u­la­to­ry af­fairs.

Pri­or to join­ing the com­pa­ny, Jalota served as vice pres­i­dent glob­al-reg­u­la­to­ry strat­e­gy head, on­col­o­gy at Bay­er Health­care. Be­fore that, Jalota had stints at Sanofi-Aven­tis, For­est Lab­o­ra­to­ries and Proc­tor and Gam­ble.

Chelsea Place John­son Linkedin

Chelsea Place John­son has joined the ear­ly-stage VC At­las Ven­ture as its se­nior as­so­ciate, fo­cus­ing on new com­pa­ny for­ma­tion across ar­eas of un­met med­ical need. John­son, who most re­cent­ly man­aged busi­ness de­vel­op­ment for Tan­go Ther­a­peu­tics, had pre­vi­ous­ly worked at Third Rock Ven­tures.

→ As Ac­celeron Phar­ma ap­proach­es the fin­ish line with lus­pa­ter­cept, co-founder Tom Ma­ni­atis is re­tir­ing from the board while con­tin­u­ing to ad­vise the com­pa­ny’s de­vel­op­ment of TGF-be­ta su­per­fam­i­ly ther­a­peu­tics. Ma­ni­atis co-found­ed the com­pa­ny in 2003 and has since tak­en up a CEO role at New York Genome Cen­ter, which he al­so helped start.

Do­main Ther­a­peu­tics — a bio­phar­ma­ceu­ti­cal com­pa­ny spe­cial­ized in the dis­cov­ery and de­vel­op­ment of new drug can­di­dates tar­get­ing trans­mem­brane re­cep­tors, in par­tic­u­lar, G pro­tein-cou­pled re­cep­tors (GPCRs) — an­nounced the ap­point­ment of Sylvie Rycke­busch to its board of di­rec­tors.

Rycke­busch was most re­cent­ly the CBO the non­prof­it Es­peR­are Foun­da­tion. In ad­di­tion, her ex­pe­ri­ence spans to roles at Mer­ck Serono and as the founder of Oc­tave Biotech Con­sult­ing.

 

Lina Gugucheva, NewAmsterdam Pharma CBO

Phar­ma group bets up to $1B-plus on the PhI­II res­ur­rec­tion of a once dead-and-buried LDL drug

Close to 5 years after then-Amgen R&D chief Sean Harper tamped the last spade of dirt on the last broadly focused CETP cholesterol drug — burying their $300 million upfront and the few remaining hopes for the class with it — the therapy has been fully resurrected. And today, the NewAmsterdam Pharma crew that did the Lazarus treatment on obicetrapib is taking another big step on the comeback trail with a €1 billion-plus regional licensing deal, complete with close to $150 million in upfront cash.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

How pre­pared is bio­phar­ma for the cy­ber dooms­day?

One of the largest cyberattacks in history happened on a Friday, Eric Perakslis distinctly remembers.

Perakslis, who was head of Takeda’s R&D Data Sciences Institute and visiting faculty at Harvard Medical School at the time, had spent that morning completing a review on cybersecurity for the British Medical Journal. Moments after he turned it in, he heard back from the editor: “Have you heard what’s going on right now?”

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pearl Huang, Dunad Therapeutics CEO (Ken Richardson, PR Newswire)

Long­time biotech leader Pearl Huang takes the reins as CEO of No­var­tis-backed up­start

It has only been a few months since Pearl Huang exited the top seat at Cygnal Therapeutics, but now she’s back at the helm of another biotech.

After taking a few months off — passing an exam in that time to get her captain’s license from the US Coast Guard — she’s been named CEO of Dunad Therapeutics, a biotech focused on developing a small molecule covalent therapies that was founded in 2020. Huang told Endpoints News that two factors attracted her to going back to the c-suite: the company’s technology and its co-founders.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Matt Gline, Roivant CEO (John Sciulli/Getty Images for GLG)

Roivant chops sick­le cell gene ther­a­py, der­ma­tol­ogy drugs to fo­cus on 'high­er val­ue pro­ject­s'

Roivant is sweeping a suite of drugs, including a gene therapy for sickle cell disease already in the clinic, out of its pipeline.

Six programs from four of its “vants” are being wound down as part of “a company-wide cost optimization and pipeline reprioritization initiative to reduce our expected operating expenses and prioritize our capital resources.”

When reached by Endpoints News, a spokesperson said, “We don’t anticipate a material reduction in headcount but we will likely reassign some folks to higher value projects as part of winding down specific programs.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Laurence Reid, Decibel CEO

Still in pre­clin­i­cal test­ing for ear gene ther­a­pies, Deci­bel touts small snap­shot of chemo-in­duced hear­ing loss drug

Though Decibel Therapeutics has largely pivoted toward gene therapies for the inner ear, its lead clinical candidate simply aims to protect cancer patients from chemotherapy-induced hearing loss. On Tuesday, the biotech presented its first efficacy data for the program, and execs like what they see.

Decibel reported interim results from a Phase Ib study showing the experimental drug, dubbed DB-020, largely protected a small group of patients from losing their hearing. Researchers used a particularly unique study design, administering the compound in one of each patients’ ears before they received cisplatin chemotherapy and placebo in the other.

Ben Zimmer, Priovant CEO

Roivant un­veils lat­est spin­out as Pfiz­er en­trusts JAK1/TYK2 to Pri­o­vant

In November, Pfizer disclosed it’s spun out the Phase II dual JAK1/TYK2 inhibitor to a startup formed in collaboration with an unnamed, experienced partner.

We now know who the partner is. And as Pfizer and Roivant officially take the wraps off Priovant Therapeutics, the companies reveal that they have started two registrational trials of the drug, brepocitinib, as part of a broader plan to develop a big, first-in-class franchise spanning multiple orphan and specialty autoimmune diseases.

Alex­ion puts €65M for­ward to strength­en its po­si­tion on the Emer­ald Isle

Ireland has been on a roll in 2022, with several large pharma companies announcing multimillion-euro projects. Now AstraZeneca’s rare disease outfit Alexion is looking to get in on the action.

Alexion on Friday announced a €65 million ($68.8 million) investment in new and enhanced capabilities across two sites in the country, including at College Park in the Dublin suburb of Blanchardstown and the Monksland Industrial Park in the central Irish town of Athlone, according to the Industrial Development Agency of Ireland.

State bat­tles over mifepri­s­tone ac­cess could tie the FDA to any post-Roe cross­roads

As more than a dozen states are now readying so-called “trigger” laws to kick into effect immediate abortion bans following the overturning of Roe v. Wade on Friday, these laws, in the works for more than a decade in some states, will likely kick off even more legal battles as states seek to restrict the use of prescription drug-based abortions.

Since Friday’s SCOTUS opinion to overturn Americans’ constitutional right to an abortion after almost 50 years, reproductive rights lawyers at Planned Parenthood and other organizations have already challenged these trigger laws in Utah and Louisiana. According to the Guttmacher Institute, other states with trigger laws that could take effect include Arkansas, Idaho, Kentucky, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas, and Wyoming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.